 |
|
All Releases
 |
OXiGENE Announces Clinical Data From FACT Study to be Presented at the 14th International Thyroid Congress
Jun 24, 2010
|
10.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jun 24, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from its clinical trials of ZYBRESTAT and chemotherapy in patients with anaplastic thyroid cancer (ATC...
|
|
OXiGENE Presents Encouraging Preclinical Data on ZYBRESTAT Ophthalmology Program
Jun 22, 2010
|
11.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jun 22, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical d...
|
|
OXiGENE Completes Enrollment of ZYBRESTAT Phase 2 Trial in Non-Small Cell Lung Cancer
Jun 16, 2010
|
11.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jun 16, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase...
|
|
OXiGENE Reports Positive Data From Phase 1 Study of OXi4503 at the 2010 ASCO Annual Meeting
Jun 7, 2010
|
13.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jun 7, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that in collaboration with OXiGENE, Professor Gordon Rustin and colleagues from the Mount Vernon Cancer Research ...
| |
|
1.0 MB |
|
|
|
OXiGENE Reports Encouraging Safety and Efficacy Data from Ongoing Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2010 ASCO Annual Meeting
Jun 6, 2010
|
13.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jun 6, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase...
| |
|
2.4 MB |
|
|
|
OXiGENE Announces Publication of Preclinical Data on OXi4503 Demonstrating Potent Anti-Leukemic Effects
May 27, 2010
|
11.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 27, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced publication of preclinical data on its second-generation, dual-action vascular disrupting agent (VDA)...
|
|
OXiGENE Announces Clinical Data to be Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology
May 18, 2010
|
12.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 18, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from clinical trials involving its vascular disrupting agent (VDA) product candidates...
|
|
OXiGENE Reports First Quarter 2010 Financial Results
May 11, 2010
|
17.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 11, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and...
|
|
OXiGENE Announces First Quarter 2010 Earnings Conference Call and Webcast
May 5, 2010
|
9.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 5, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report first quarter 2010 results on Tuesday, May 11, 2010. A conference call and webcast hosted by OXiGENE...
|
|
OXiGENE Applies for Voluntary Delisting From the Stockholm Exchange
Apr 23, 2010
|
10.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Apr 23, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has applied for the voluntary delisting of OXiGENE common shares from the Stockholm Stock Exchange (SSE)....
|
|
OXiGENE Regains Compliance With NASDAQ Listing Requirements
Apr 7, 2010
|
8.4 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Apr 7, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has received a letter from NASDAQ Global Market exchange confirming that, with the appointment of Tamar Ho...
|
|
OXiGENE Appoints Tamar D. Howson and Peter J. Langecker to Its Board of Directors
Apr 5, 2010
|
11.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Apr 5, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced the appointment of Tamar Howson and its current CEO, Dr. Peter J. Langecker, to its Board of Directors.
Ms. Ho...
|
|
OXiGENE Announces Going Concern Opinion On Its Audited Financial Statements for 2009
Mar 19, 2010
|
8.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Mar 19, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that the audit report from its independent registered public accounting firm on its financial statements for the ...
|
|
OXiGENE Announces Change to Board of Directors
Mar 15, 2010
|
8.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Mar 15, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that Arthur B. Laffer, Ph.D , has resigned from the Company's Board of Directors to pursue other longstanding int...
|
|
OXiGENE Announces $7.5 Million Financing
Mar 11, 2010
|
10.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Mar 11, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,5...
|
|
OXiGENE Reports Fourth Quarter and Year-End 2009 Results
Feb 25, 2010
|
21.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 25, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and year ending December 31, 2009. The Company also provided an upda...
|
|
OXiGENE Announces Fourth Quarter and Fiscal 2009 Earnings Conference Call and Webcast
Feb 19, 2010
|
9.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 19, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report fourth quarter and fiscal year-end 2009 results, along with guidance for 2010, on Thursday, Februar...
|
|
OXiGENE Announces Restructuring to Focus Resources on Key Programs and Provides Business Update
Feb 11, 2010
|
11.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 11, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today a restructuring plan designed to focus resources on the company's highest-value clinical assets...
|
|
OXiGENE Announces Results of Stockholder Vote on Proposed Merger With VaxGen
Feb 4, 2010
|
9.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 4, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that at the special meeting of stockholders of OXiGENE held yesterday, the issuance of shares of...
|
|
OXiGENE Reports Promising Preclinical Data Using OXi4503 in Acute Myelogenous Leukemia Models at ASH Conference
Dec 7, 2009
|
13.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 7, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced the presentation of data from preclinical studies carried out by Christopher R. Cogle, M.D., Ass...
|
|
|
= add release to Briefcase |
|
 |
|
3:59 PM ET - 07/29/10 |
|
$0.34
( 0.00)
|
Volume | 914,500 |
Day High | 0.37 |
Day Low | 0.33 |
52-week High | 1.75 |
52-week Low | 0.27 |
» more |
|
|
|
|
 |
|
 |
|
Shareholder Briefcase
Download Library
RSS News Feeds
| |
|
|
|
|
